MERIDIAN BIOSCIENCE, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 10 rows in 2019. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2019-11-05: Reporting owner Kenny John P.; Form 4; Security Stock Options (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2019-01-24: Reporting owner Williams Felicia; Form 4; Security Stock Options (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2019-01-24: Reporting owner Sazdanoff Catherine; Form 4; Security Stock Options (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2019-01-24: Reporting owner Rice John McCune Jr.; Form 4; Security Stock Options (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2019-11-05 | Kenny John P. Director, Officer (Chief Executive Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +198,119 198,119 owned after | $10.10 exercise price | 2019-11-07 | |
| 2019-01-24 | Williams Felicia Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,740 8,740 owned after | $16.97 exercise price | 2019-01-28 | |
| 2019-01-24 | Sazdanoff Catherine Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,740 8,740 owned after | $16.97 exercise price | 2019-01-28 | |
| 2019-01-24 | Rice John McCune Jr. Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,740 8,740 owned after | $16.97 exercise price | 2019-01-28 | |
| 2019-01-24 | PHILLIPS DAVID Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,740 8,740 owned after | $16.97 exercise price | 2019-01-28 | |
| 2019-01-24 | McIlwraith John Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,740 8,740 owned after | $16.97 exercise price | 2019-01-28 | |
| 2019-01-24 | Ellingwood Dwight E Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,740 8,740 owned after | $16.97 exercise price | 2019-01-28 | |
| 2019-01-24 | Anderson James M. Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,740 8,740 owned after | $16.97 exercise price | 2019-01-28 | |
| 2019-01-07 holding as of filing | Baldasare Bryan T Officer (Chief Accounting Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $19.71 exercise price | 2019-01-07 | ||
| 2019-01-07 holding as of filing | Baldasare Bryan T Officer (Chief Accounting Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $19.56 exercise price | 2019-01-07 |